Opens in a new tab

Deep Vein Thrombosis (DVT): Symptoms, D-Dimer Test and Treatment

Table of Content

Friendly doctor gently examining the calf of a smiling older man sitting on an exam table, with a compression ultrasound device, a lab report and a pill organiser nearby

⚕️ This article is for informational purposes only and does not replace medical advice. Always consult your doctor to interpret your results.

Deep vein thrombosis (DVT) is a blood clot in a deep vein, most often in the calf, thigh or pelvis. Typical DVT symptoms are swelling, pain or tenderness, warmth and redness or discoloration of one leg, but about half of people with a DVT have no symptoms at all. The main danger is that part of the clot breaks off and travels to the lungs, causing a pulmonary embolism. In the United States, as many as 900,000 people may be affected by DVT or pulmonary embolism each year, according to the CDC.

Doctors diagnose DVT in steps: a clinical score (the Wells score), a D-dimer blood test when the score is low, and a compression ultrasound of the leg. Treatment is a blood thinner (anticoagulant) for at least 3 months, usually apixaban or rivaroxaban. Most clots settle, but long-term leg symptoms and recurrences are common, so the length of treatment matters.

Key takeaways

  • A swollen, painful, warm leg on one side is the classic sign of a blood clot in the leg; chest pain or sudden shortness of breath means a possible pulmonary embolism and needs 999.
  • A normal D-dimer combined with a low Wells score safely rules out DVT without an ultrasound; after age 50, many labs use an age-adjusted cutoff (age × 10 ng/mL).
  • Before a blood thinner, doctors check blood counts with platelets, kidney and liver function, PT/INR and aPTT.
  • Thrombophilia (inherited clotting) testing is not useful for most people; the 2023 American Society of Haematology (ASH) guideline limits it to a few specific situations.
  • Recent trials (2025) show that a lower dose of apixaban or rivaroxaban can be used for long-term prevention with less bleeding, and factor XI inhibitors are the next generation of blood thinners under study.

What is deep vein thrombosis?

The deep veins run inside the leg muscles and carry blood back to the heart. When a clot (thrombus) forms in one of them, it blocks the flow and the leg swells. MedlinePlus notes that DVT usually affects one side, most often the lower leg or thigh, but it can also occur in the arm or pelvis, for example around a long-term catheter.

DVT and pulmonary embolism are two forms of one disease, venous thromboembolism (VTE), which affects about 1 to 2 people per 1,000 each year (ASH 2020). The CDC estimates that 60,000 to 100,000 Americans die of VTE each year. If the clot has reached the lungs, read our guide to pulmonary embolism symptoms, tests and treatment.

Proximal and distal DVT

A proximal DVT involves the vein behind the knee or higher; a distal DVT stays in the calf. Isolated distal DVT makes up to 50% of leg DVTs on ultrasound, and most do not extend to the thigh (Vasa, 2024). Proximal clots carry a higher risk of pulmonary embolism.

What causes deep vein thrombosis?

Three things favour a clot: slow blood flow, damage to the vein wall and blood that clots too easily. The CDC lists injury to a vein, limited movement, higher oestrogen levels, chronic illness, older age and family history.

Risk factors for a blood clot in the leg

  • Surgery and hospital stays: risk is highest in the first 3 months after surgery (NHLBI), and more than a third of VTE cases follow a recent hospitalisation, mostly after discharge (CDC).
  • Immobility: bed rest, a leg cast, or a flight of more than 4 hours.
  • Age: the chance of VTE nearly doubles every 10 years after 40 (NHLBI).
  • Cancer and its treatments, obesity, infections such as COVID-19, and autoimmune diseases such as lupus.
  • Pregnancy, childbirth within 6 months, oestrogen pills or hormone therapy, especially with smoking (MedlinePlus).
  • A previous clot, a family history, or inherited conditions such as factor V Leiden, the prothrombin variant, or antithrombin, protein C or protein S deficiency.

Doctors label each clot provoked (temporary trigger such as surgery or a cast), cancer-associated, or unprovoked. This label drives how long to treat.

DVT symptoms and warning signs

The CDC lists four signs of a DVT: swelling of the leg or arm, pain or tenderness, warmth, and redness or a change in skin colour.

Early stage DVT symptoms in the leg

Early signs can be subtle: a calf that feels heavy or tight, one ankle more marked by the sock, or pain when walking. Swelling on one side is the best clue; in the Wells score, a calf at least 3 cm larger than the other counts. About half of DVTs cause no symptoms (CDC) and are found by chance.

Signs of a pulmonary embolism

A clot in the lungs causes difficulty breathing, a fast heartbeat, chest pain that worsens with a deep breath or a cough, coughing up blood, or fainting (CDC). Sudden death is the first symptom in about one quarter of people with a pulmonary embolism.

How do you know if you have deep vein thrombosis?

DVT is confirmed by imaging. The ASH 2018 diagnosis guideline recommends estimating the probability first, using the D-dimer test first in people at low risk, and going straight to ultrasound in people at high risk.

Step 1: the Wells score for DVT

The Wells score was tested in a 2003 trial of 1,096 outpatients (New England Journal of Medicine). The two-level version used by NICE gives 1 point each for: active cancer; paralysis, weakness or a recent leg cast; bed rest of 3 days or more or major surgery within 12 weeks; tenderness along the deep veins; an entirely swollen leg; calf swelling at least 3 cm larger than the other side; pitting oedema in the painful leg only; non-varicose collateral surface veins; and a previous DVT. It subtracts 2 points if another diagnosis is at least as likely. A score of 2 or more means DVT is "likely"; 1 or less, "unlikely."

Step 2: the D-dimer blood test

D-dimer is a fragment released when a clot breaks down. A normal result means a clot is probably absent; a high result needs more tests, because D-dimer also rises with pregnancy, recent surgery, older age, immobility and some chronic diseases, and blood thinners can falsely lower it (MedlinePlus). In the 2003 Wells trial, a negative D-dimer in "unlikely" patients let 39% skip ultrasound, with only 0.4% developing a clot over 3 months. Our D-dimer test guide explains how to read your number.

The age-adjusted D-dimer cutoff

D-dimer rises with age, so the usual cutoff of 500 µg/L (500 ng/mL, or 0.50 mg/L) is often exceeded in older adults without a clot. A 2013 BMJ meta-analysis of 13 cohorts (12,497 patients) tested age × 10 µg/L after 50. Over 80, the standard cutoff correctly reassured only 14.7% of people without a clot, compared with 35.2% for the age-adjusted cutoff, while sensitivity stayed above 97%. For a 75-year-old, the threshold becomes 750 ng/mL (0.75 mg/L). Check the unit on your report (FEU or DDU).

Step 3: compression ultrasound

A vein that does not collapse under the probe contains a clot. NICE recommends a proximal leg ultrasound, ideally within 4 hours, when DVT is likely, and a repeat scan 6 to 8 days later if the scan is negative but the D-dimer is positive.

Lab work before anticoagulation

NICE recommends baseline blood tests including a full blood count, kidney and liver function, prothrombin time (PT) and activated partial thromboplastin time (aPTT), without delaying treatment, with results reviewed within 24 hours.

  • Full blood count: haemoglobin looks for anaemia or hidden bleeding, and the platelet count checks that anticoagulation is safe.
  • Kidney function: creatinine clearance decides the drug and dose; NICE lists specific options between 15 and 50 mL/min. See our creatinine guide.
  • Liver function: liver disease can prolong clotting times and affect drug clearance; see our liver function tests guide.
  • PT/INR and aPTT: they detect a bleeding tendency, and the INR monitors warfarin (target 2.0 to 3.0, ASH 2020). Our coagulation panel guide explains them together.

Thrombophilia testing: when and when not

Tests for inherited or acquired clotting conditions include factor V Leiden, the prothrombin variant, antithrombin III, protein C, protein S and antiphospholipid antibodies (MedlinePlus). A positive result rarely changes treatment.

  • NICE: do not test after a provoked DVT, and do not test for inherited thrombophilia while anticoagulation continues, because blood thinners distort several tests.
  • NICE: consider antiphospholipid antibodies after an unprovoked DVT if stopping treatment is planned; triple-positive antiphospholipid syndrome is treated with warfarin, not a DOAC.
  • ASH 2023: test only in narrow cases, such as a hormone-related clot or a family history of antithrombin, protein C or protein S deficiency, and never as a screen before birth control pills.

Should you be checked for cancer?

After an unprovoked clot, NICE recommends a history, an exam and the baseline blood tests, but no further cancer search unless symptoms or signs point to cancer.

Key numbers in DVT diagnosis and treatment (UK and US units)

MeasureValue (UK units)Other unitsWhat it means
Wells score, two-level≥ 2 points likely; ≤ 1 unlikelySameLikely: ultrasound first. Unlikely: D-dimer first
D-dimer, standard cutoff500 ng/mL (FEU)0.50 mg/L (500 µg/L)Below with low Wells score: DVT ruled out
D-dimer, age-adjusted (over 50)Age × 10 ng/mL (e.g. 750 at age 75)Age × 0.01 mg/L (e.g. 0.75)Fewer false positives in older adults
Calf difference (Wells)≥ 3 cm≥ 1.2 inAdds 1 point
INR target on warfarin2.0 to 3.0Same (ratio)Therapeutic range for VTE
Creatinine clearance15 to 50 mL/min0.25 to 0.83 mL/sRenal impairment: drug and dose adapted
Platelets (trial exclusion, API-CAT)Below 75 × 10⁹/LBelow 75,000/µLLow platelets need specialist dosing
Haemoglobin (trial exclusion, API-CAT)Below 80 g/LBelow 8 g/dLLook for bleeding before treating
Body weight (NICE)Below 50 kg or above 120 kgBelow 110 lb or above 265 lbConsider drug level monitoring

How to read your results

  • Low Wells score and normal D-dimer: DVT is ruled out.
  • High D-dimer, normal ultrasound: no proximal clot today; a repeat scan may follow.
  • Positive ultrasound: DVT confirmed, and your baseline tests guide the drug. Our aPTT guide and PT and INR guide explain prolonged clotting times.

DVT treatment

Anticoagulants stop the clot from growing and prevent new ones while the body breaks it down. ASH 2020 prefers direct oral anticoagulants (DOACs) over warfarin and home treatment for uncomplicated DVT.

Blood thinners for DVT

  • DOACs: apixaban, rivaroxaban, dabigatran, edoxaban. NICE offers apixaban or rivaroxaban first; dabigatran and edoxaban follow at least 5 days of heparin. Apixaban blocks factor Xa (ChEMBL, first approved in 2011).
  • Low-molecular-weight heparin: injections, used in pregnancy and in some cancers or kidney failure.
  • Warfarin: needs INR checks; kept for cases such as triple-positive antiphospholipid syndrome.

How long does DVT treatment last?

NICE recommends at least 3 months for a proximal DVT (3 to 6 months with active cancer), then a review. After a provoked DVT whose trigger has resolved, treatment usually stops at 3 months; after an unprovoked DVT, longer treatment is considered, weighing clot risk against bleeding. ASH 2020 recommends indefinite treatment after recurrent unprovoked VTE. For a calf DVT, the RIDTS trial (402 patients, BMJ 2022) found fewer recurrences with 12 weeks of rivaroxaban than with 6 (11% versus 19%), without major bleeding.

Procedures and filters

In the ATTRACT trial (692 patients, NEJM 2017), adding catheter-directed thrombolysis did not lower post-thrombotic syndrome (47% versus 48%) and increased major bleeding; NICE keeps it for selected recent iliofemoral DVTs. An inferior vena cava filter catches clots but does not prevent new ones (NHLBI); it is for people who cannot take blood thinners.

Does a deep vein thrombosis go away?

DVT often goes away without problems but can come back, sometimes years later (MedlinePlus). About one third of people with VTE have a recurrence within 10 years, and one third to one half of people with DVT develop post-thrombotic syndrome: chronic swelling, heaviness and skin changes (CDC). In the SOX trial (806 patients, Lancet 2014), compression stockings did not prevent it compared with placebo stockings (14.2% versus 12.7%).

Preventing DVT

  • Move as soon as possible after surgery or illness, and ask about preventive blood thinners in the hospital (CDC).
  • On trips over 4 hours, walk every 1 to 2 hours and flex your calves while seated (CDC).
  • Keep a healthy weight, stay active and mention any past clot before surgery, pregnancy or hormones.

As many as 70% of healthcare-associated VTE cases are preventable (CDC).

DVT in pregnancy and cancer

Pregnancy and after childbirth

VTE complicates about 1.2 of every 1,000 deliveries and is a leading cause of maternal illness and death (ASH 2018). D-dimer naturally rises in pregnancy, so ultrasound matters more. ASH strongly favours low-molecular-weight heparin and recommends prevention during pregnancy after a past unprovoked or hormone-related clot. See blood tests during pregnancy.

Cancer-associated thrombosis

A 2026 review calls cancer-associated VTE the second leading cause of death in people with cancer, with the highest risk in pancreatic, gastric, brain and lung cancers. The 2023 ASCO update added apixaban as a treatment option (strong recommendation), and NICE suggests a DOAC for most people with active cancer.

When to see a doctor

  • See a GP the same day, or call NHS 111, if one leg (or arm) becomes swollen, painful, warm or red without a clear reason, especially after surgery, a long trip, childbirth or a cast.
  • Call 999 or go to A&E if you have sudden shortness of breath, chest pain that worsens when you breathe in, a fast heartbeat, coughing up blood, fainting or severe lightheadedness: these can be signs of a pulmonary embolism.
  • If you take a blood thinner, seek urgent care for black stools, vomiting blood, blood in the urine, a severe headache or any heavy bleeding.

Latest scientific advances in deep vein thrombosis

Lower-dose blood thinners for long-term prevention (2025)

In RENOVE (2,768 patients, Lancet 2025, NCT03285438), reduced-dose apixaban (2.5 mg twice daily) or rivaroxaban (10 mg daily) gave very low recurrence rates (2.2% versus 1.8% at 5 years on full dose) without formally meeting its non-inferiority goal, and cut clinically relevant bleeding from 15.2% to 9.9%. In HI-PRO (600 patients, NEJM 2025, NCT04168203), people with a provoked VTE and an enduring risk factor had 1.3% recurrences on apixaban 2.5 mg twice daily for a year, versus 10.0% on placebo.

Reduced-dose apixaban in cancer (API-CAT, 2025)

The API-CAT trial (1,766 people with active cancer, NEJM 2025, NCT03692065) compared apixaban 2.5 mg and 5 mg twice daily after at least 6 months of treatment. Recurrent clots were similar (2.1% versus 2.8%), and clinically relevant bleeding was lower with the reduced dose (12.1% versus 15.6%).

Thrombophilia testing narrowed (ASH 2023)

The ASH 2023 guideline issued 23 recommendations, nearly all on very low certainty evidence. It advises against testing most people with a clot and supports testing only when the result would change a decision, such as continuing anticoagulation after a hormone-related clot.

Factor XI inhibitors: the next blood thinners (2023-2026)

Factor XI helps clots grow but matters less for stopping bleeding, so blocking it could prevent clots with less bleeding. A 2026 review in Current Opinion in Haematology notes that the antibody abelacimab cut bleeding by 62% versus rivaroxaban in atrial fibrillation, and sees the best fit in cancer-associated thrombosis. Two phase 3 trials of abelacimab in cancer-associated VTE, ASTER (versus apixaban, NCT05171049) and MAGNOLIA (versus dalteparin, NCT05171075), were ended by sponsor decision in 2026 (ClinicalTrials.gov); results are awaited. The factor XI antibodies REGN9933 and REGN7508 are being tested to prevent catheter clots (ROXI-PEAK, NCT07697599). None is approved for DVT yet.

Which tests can help?

For a suspected clot, the D-dimer is read with the Wells score and the ultrasound decides. Once DVT is confirmed, expect a full blood count with platelets, creatinine, liver enzymes, PT/INR and aPTT; the INR is then checked regularly on warfarin, and NICE advises reviewing long-term anticoagulation at least once a year. Thrombophilia tests are planned with a specialist, usually when stopping treatment is considered.

Glossary

  • Anticoagulant: a medicine that slows blood clotting, often called a blood thinner.
  • DOAC: direct oral anticoagulant, such as apixaban, rivaroxaban, dabigatran or edoxaban.
  • D-dimer: a fragment released when a clot breaks down; a normal level helps rule out a clot.
  • Proximal DVT: a clot in the vein behind the knee or higher; distal DVT: a clot in the calf veins only.
  • Post-thrombotic syndrome: long-term pain, swelling and skin changes in a leg after a DVT.
  • Thrombophilia: an inherited or acquired tendency to form clots.
  • Wells score: a point score that estimates how likely a DVT is before testing.

Frequently asked questions

How do you know if you have deep vein thrombosis?

Suspect a DVT if one leg is swollen, painful, warm or red, especially after surgery, a long trip or a period in bed. Only a doctor can confirm it: a Wells score and a D-dimer blood test rule it out when both are low, and a compression ultrasound of the leg shows the clot.

What is the main cause of deep vein thrombosis?

There is rarely a single cause. Most DVTs combine slow blood flow (immobility, surgery, long flights), vein damage and blood that clots more easily (hormones, pregnancy, cancer, inherited conditions). Recent surgery or a hospital stay is the most common trigger.

What are the five warning signs of a blood clot?

In the leg: swelling, pain or tenderness, warmth, and redness or discoloration. The fifth sign to never ignore is sudden shortness of breath or chest pain, which can mean the clot has reached the lungs; call 999.

What are early stage DVT symptoms in the leg?

A calf that feels tight, heavy or crampy, slight swelling of one ankle or calf, and pain when walking or flexing the foot. These signs can be mild, and about half of DVTs cause no symptoms.

Does a deep vein thrombosis go away?

Yes, most clots shrink and the body breaks them down over weeks to months while you take a blood thinner. However, about one third of people have another clot within 10 years, and one third to one half develop post-thrombotic syndrome, so follow-up matters.

What is the treatment for deep vein thrombosis?

A blood thinner for at least 3 months, usually apixaban or rivaroxaban, often at home. Longer treatment, sometimes at a reduced dose, is discussed after an unprovoked clot or with ongoing risk factors.

Can a normal D-dimer rule out a blood clot in the leg?

Yes, when your doctor's Wells score says DVT is unlikely. If the score is high, an ultrasound is needed whatever the D-dimer result. After age 50, many labs use an age-adjusted cutoff of age × 10 ng/mL.

Sources

  • Centers for Disease Control and Prevention — Data and statistics on venous thromboembolism — CDC, 2025 — cdc.gov
  • Centers for Disease Control and Prevention — About venous thromboembolism (blood clots) — CDC — cdc.gov
  • National Heart, Lung, and Blood Institute — Venous thromboembolism: causes and risk factors — NHLBI — nhlbi.nih.gov
  • National Heart, Lung, and Blood Institute — Venous thromboembolism: treatment — NHLBI — nhlbi.nih.gov
  • MedlinePlus — Deep venous thrombosis — National Library of Medicine — medlineplus.gov
  • MedlinePlus — D-dimer test — National Library of Medicine — medlineplus.gov
  • National Institute for Health and Care Excellence — Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158) — NICE, 2020, updated 2023 — nice.org.uk
  • Wells PS, Anderson DR, Rodger M et al. — Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis — N Engl J Med, 2003 — doi.org
  • Schouten HJ, Geersing GJ, Koek HL et al. — Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis — BMJ, 2013 — doi.org
  • Lim W, Le Gal G, Bates SM et al. — American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism — Blood Adv, 2018 — doi.org
  • Ortel TL, Neumann I, Ageno W et al. — American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism — Blood Adv, 2020 — doi.org
  • Middeldorp S, Nieuwlaat R, Baumann Kreuziger L et al. — American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing — Blood Adv, 2023 — doi.org
  • Bates SM, Rajasekhar A, Middeldorp S et al. — American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy — Blood Adv, 2018 — doi.org
  • Key NS, Khorana AA, Kuderer NM et al. — Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update — J Clin Oncol, 2023 — doi.org
  • Righini M, Robert-Ebadi H — Management of isolated distal deep vein thrombosis — Vasa, 2024 — doi.org
  • Ageno W, Bertu L, Bucherini E et al. — Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial (RIDTS) — BMJ, 2022 — doi.org
  • Kahn SR, Shapiro S, Wells PS et al. — Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial (SOX) — Lancet, 2014 — doi.org
  • Vedantham S, Goldhaber SZ, Julian JA et al. — Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis (ATTRACT) — N Engl J Med, 2017 — doi.org
  • Couturaud F, Schmidt J, Sanchez O et al. — Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence (RENOVE) — Lancet, 2025 — doi.org
  • Piazza G, Bikdeli B, Pandey AK et al. — Apixaban for extended treatment of provoked venous thromboembolism (HI-PRO) — N Engl J Med, 2025 — doi.org
  • Mahé I, Carrier M, Mayeur D et al. — Extended reduced-dose apixaban for cancer-associated venous thromboembolism (API-CAT) — N Engl J Med, 2025 — doi.org
  • Di Leo G, Bordonaro CA, Capodanno D et al. — Antithrombotic therapy for cancer-associated venous thromboembolism — Clin Res Cardiol, 2026 — doi.org
  • Kidder E, Dhanesha N — Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning — Curr Opin Hematol, 2026 — doi.org
  • Anthos Therapeutics — Abelacimab versus apixaban in cancer-associated VTE (ASTER) — ClinicalTrials.gov — NCT05171049
  • NHS — DVT (deep vein thrombosis) — NHS, accessed 2026 — https://www.nhs.uk/conditions/deep-vein-thrombosis-dvt/

Further reading

Understand your lab results with AI DiagMe

A high D-dimer, a prolonged PT or aPTT, or a platelet count flagged on your report can be worrying before your appointment. AI DiagMe reads your blood test report in minutes, explains each value in plain language and suggests questions to ask your doctor. Upload your lab results to AI DiagMe for a clear, personal report.

Editorial team

  • AI DiagMe

    Author

    The AI DiagMe team brings together physicians, clinical specialists, and medical editors. Our articles are written by health communication professionals and then reviewed and validated by the physicians of our scientific committee, composed of practising hospital physicians in specialties such as haematology, endocrinology, and general medicine. Julien Priour, who leads the editorial mission, holds an MBA from HEC Paris and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). Each piece of content is based on current clinical guidelines and peer-reviewed medical publications.

    Email Website
  • Julien Priour

    Edited by

    Co-founder and CEO of AI DiagMe · Senior medical editor · HEC Paris graduate

    Julien Priour is a senior medical editor at AI DiagMe, where he oversees the editorial line and the fact-checking process. A graduate of HEC Paris, he has 3 years of experience in health publishing and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). He makes sure that every article follows current medical guidelines and is reviewed and validated by a physician from the scientific and ethics committee. He sets the sourcing standards (HAS, Ameli, INSERM…) and the review standards applied across the entire site.

    Email LinkedIn
  • Dr. Claude Tchonko

    Medically reviewed by

    Dr Claude Tchonko is a haematologist, in practice since 2013, currently working at Clinique Mas de Rochet (Castelnau-le-Lez, France). With an international background, he specialises in the management of haematological malignancies (leukemias, lymphomas, myelomas), with particular expertise in autologous stem cell transplantation, CAR-T cell therapy and the optimisation of care pathways in onco-haematology.

    Author of a reference work, ‘Lymphoid Haematological Malignancies in Mali’, he combines clinical practice with active involvement in projects developing technology solutions for healthcare.

    He holds a State Doctorate in Medicine (Faculty of Medicine of Bamako, 2006) and completed his training with a Certificate of Specialized Studies in Bioclinical Haematology (Abidjan-Cocody, 2010) and several university diplomas: a DFMS in Haematology and an inter-university diploma (DIU) in Onco-Haematological Cytogenetics (Grenoble), as well as a university diploma (DU) in major sickle cell disease (UPEC).

    Dr. Claude Tchonko LinkedIn

Related Posts

Coming soon